Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 143Myelodysplastic Syndromes 53Leukemia 24Leukemia, Myelomonocytic, Chronic 21Recurrence 12Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Peripheral 6Leukemia, Monocytic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm, Residual 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelomonocytic, Acute 5Anemia, Refractory, with Excess of Blasts 5Neoplasms 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Prostatic Neoplasms 3Primary Myelofibrosis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Pancreatic Neoplasms 2

Interventions

Etoposide 3Dexamethasone 2Cyclophosphamide 2Alemtuzumab 2tocilizumab 1sintilimab 1pegaspargase 1Whole-Body Irradiation 1Vincristine 1Prednisone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methotrexate 1Gemcitabine 1EPOCH protocol 1Doxorubicin 1Cytarabine 1Calcium Dobesilate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphohistiocytosis, Hemophagocytic × Azacitidine × Clear all
NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Sun Yat-sen University

Phase 2 Unknown
37 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡